Australia
Style3D Research Shines the Show with additional Two Papers Accepted at SIGGRAPH ASIA 2023 on Cloth Simulation Innovations
SYDNEY, Jan. 10, 2024 /PRNewswire/ -- The electrifying stage of SIGGRAPH Asia 2023 witnessed Style3D Research's triumphant unveiling of two groundbreaking research papers through captivating oral presentations. This pinnacle gathering, renowned as a global hub for computer graphics, provided the ...
Seeing Machines unveils latest Guardian technology at CES 2024
- Guardian is the company's world-leading Aftermarket Driver Monitoring System for commercial vehicles and is currently connected to 54,000 vehicles globally - The new version includes Drowsiness Detection with refined microsleep detection and eye-gaze tracking to protect drivers fro...
Canadian Solar's e-STORAGE to Deliver 220 MWh DC of Battery Storage Solutions to Epic Energy's Mannum Project in South Australia
GUELPH, ON, Jan. 8, 2024 /PRNewswire/ -- Canadian Solar Inc
Recurrent Energy Completes Sale of 100 MW/200 MWh Battery Energy Storage Project in South Australia to Epic Energy
GUELPH, ON, Jan. 8, 2024 /PRNewswire/ -- Canadian Solar Inc.
GPN Vaccines Reports Positive Safety and Immunogenicity Data from its Phase 1 Trial of Gamma-PN
ADELAIDE, Australia, Jan. 3, 2024 /PRNewswire/ -- GPN Vaccines Ltd, a clinical-stage biotechnology company developing a Streptococcus pneumoniae vaccine to prevent life-threatening pneumonia, bacteraemia and meningitis, is pleased to announce positive safety and immunogenicity data from its Phase...
APL-2301, a compound developed by Asieris for the treatment of Acinetobacter baumannii infection, was approved for Phase I clinical trials in Australia
SHANGHAI, Dec. 24, 2023 /PRNewswire/ -- Asieris Pharmaceuticals (Stock Code: 688176.SH), a global biopharma company specializing in discovering, developing and commercializing innovative drugs for the treatment of genitourinary tumors and other related diseases, announced that its product, APL-23...
Following a digital Rebrand, Little Black Book Looks Back at a Decade of Exponential Growth and Record Turnover
* LBB reports continued growth in business in the UK and an acceleration in growth internationally with increased business in theUSA, Canada, Australia, India and Germany. * A record turnover for the business of £3.2m in 2022, with a turnover of around £4m forecast in 2023. * The world's le...
Neuren Phase 2 trial shows significant improvements in Phelan-McDermid syndrome
Highlights: * Significant improvement was assessed by both clinicians and caregivers across multiple efficacy measures * Improvements were consistently seen across clinically important aspects of Phelan-McDermid syndrome, including communication, behaviour, cognition/learning and socialis...
Lunit Advances to Stage 2 of Australia's National Breast Cancer Screening Project
* After a successful stage 1, Lunit INSIGHT MMG moves to prospective validation inAustralia's BreastScreen NSW Machine Reading Solution Project SEOUL, South Korea, Dec. 11, 2023 /PRNewswire/ -- Lunit (KRX:328130.KQ), a leading provider of AI-powered solutions for cancer diagnostics and therape...
IonOpticks and Newomics broaden chromatography accessibility for Agilent mass specs, with Shimadzu pending
MELBOURNE, Australia, Dec. 6, 2023 /PRNewswire/ -- IonOpticks, the world leader in high performance liquid chromatography for mass spectrometry, is proud to announce an exciting collaboration with Newomics Inc. that has produced an interface solution for their flagship Aurora Series columns and A...
Registrational Phase III CLARIFY trial in prostate cancer commences
SYDNEY, Nov. 30, 2023 /PRNewswire/ -- Clarity Pharmaceuticals (ASX: CU6) ("Clarity"), a clinical stage radiopharmaceutical company with a mission to develop next-generation products that improve treatment outcomes for children and adults with cancer, is pleased to announce it has commenced its r...
First patient with metastatic prostate cancer to receive 2 doses of Cu-67 SAR-bisPSMA achieves undetectable PSA level
HIGHLIGHTS * Undetectable levels of Prostate Specific Antigen (PSA) have been reported from the first patient with metastatic castrate-resistant prostate cancer (mCRPC) to ever receive two cycles of Clarity's67Cu-SAR-bisPSMA at the 8GBq dose level. PSA is a marker of tumour burden, clinical re...
Leading AI decisioning platform Rich Data Co successfully raises $17.5 million in Series B round to accelerate North America expansion
SYDNEY, Nov. 29, 2023 /PRNewswire/ -- Rich Data Co
Clarity's theranostic prostate cancer trial progresses at the highest dose level cohort
HIGHLIGHTS * Cohort 3 of the theranostic SECuRE trial investigating 64Cu/67 Cu-SAR-bisPSMA in metastatic castrate-resistant prostate cancer (mCRPC) has enrolled and treated 3 participants who received therapy with67Cu-SAR-bisPSMA at the highest dose level of 12GBq. * No dose limiting toxicit...
Telstra Broadcast Services and BT Announce Strategic Alliance to Enhance Global Network Connectivity
Initial five-year agreement delivers expanded media and broadcast network footprint acrossAsia-Pacific and key regions worldwide, with enhanced access to global markets SYDNEY, Nov. 21, 2023 /PRNewswire/ -- Telstra Broadcast Services (TBS) and BT have entered into an initial five-year strateg...
First Subject Enrolled in Phase 1 Study of MRX-5
SHANGHAI, Nov. 20, 2023 /PRNewswire/ -- Recently, Shanghai MicuRx Pharmaceuticals Co., Ltd. (hereinafter referred to as "MicuRx") announced that its proprietary antibiotic MRX-5, has enrolled its first subject in the first Phase I clinical trial inAustralia. MRX-5 is a new type of benzodiazepine...
HaemaLogiX Announces Appointment of Damian Clarke-Bruce as Managing Director and CEO
SYDNEY, Nov. 13, 2023 /PRNewswire/ -- HaemaLogiX Ltd, a clinical stage Australian biotech, is pleased to announce the appointment ofDamian Clarke-Bruce as Managing Director and CEO, effective13 November 2023. Outgoing CEO Bryce Carmine will remain active in the company, retaining his role as Cha...
6clicks GRC Platform Adds Automated Cybersecurity Incident Tracking and Reporting to Meet New SEC Disclosure Requirements
Platform Now Helps Organizations Compile Details of Qualifying Events Centrally
for Tracking, Reporting, and Complete Auditability to Ensure Full Compliance
and Ease of Management
MELBOURNE, Australia, Nov. 13, 2023 /PRNewswire/ -- 6clicks
PYC'S FOURTH DRUG CANDIDATE HAS DISEASE-MODIFYING POTENTIAL IN POLYCYSTIC KIDNEY DISEASE
* PYC has developed a new drug candidate for the >5 million people worldwide [1] with Polycystic Kidney Disease (PKD) * This drug candidate has demonstrated efficacy in human models derived from the kidneys of patients with end-stage renal failure due to PKD[2] * PKD is a life-changing diseas...
Beyond2020 Improves Access to Clean Water for 10,000 Rural Malaysians
* Sustainable water fountains in 25 rural Malaysian communities provide clean, safe water, reducing waterborne illnesses ABU DHABI, UAE, Nov. 9, 2023 /PRNewswire/ -- Beyond2020, the UAE-driven humanitarian initiative, has installed water filters in 25 communities in theSabah and Sarawak regions...
Week's Top Stories
Most Reposted
Protiviti Transforms Cyber Risk Consulting with CYFIRMA's Advanced Intelligence-Led Cybersecurity
[Picked up by 324 media titles]
2024-04-15 09:00Sephora appoints Xia Ding as Managing Director of Sephora Greater China
[Picked up by 309 media titles]
2024-04-15 17:33AI-DOL: Revolutionising the Future of Entertainment with AI-Powered Virtual Idols
[Picked up by 295 media titles]
2024-04-12 15:14Animated Life in Yunnan
[Picked up by 275 media titles]
2024-04-18 14:00Allianz Partners Introduces Instant Online Chat for HCF Travel Insurance Customers
[Picked up by 275 media titles]
2024-04-15 08:00